NeuroResponse is a healthcare company that provides patients with Multiple Sclerosis necessary access to clinicians to obtain medications.
NeuroResponse has raised $1.3M in total funding. The most recent round was Grant. The last funding was announced in December 2021.
NeuroResponse's investors include SBRI Healthcare.
NeuroResponse is headquartered in London, United Kingdom.
NeuroResponse is a healthcare company that provides patients with Multiple Sclerosis necessary access to clinicians to obtain medications.
NeuroResponse is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NeuroResponse — Funding & Investors." VCBacked, December 20, 2021, https://www.vcbacked.co/company/neuroresponse. Accessed September 30, 2026.
VCBacked. (2021). NeuroResponse — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/neuroresponse
{{cite web |title=NeuroResponse — Funding & Investors |url=https://www.vcbacked.co/company/neuroresponse |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated